Market Lens IQ is a global market intelligence and strategic consulting firm delivering advanced syndicated research reports, customized industry analysis, competitive intelligence, and data-driven advisory solutions to organizations across international markets. With a strong commitment to analytical excellence and innovation, Market Lens IQ empowers enterprises, investors, consultants, and decision-makers with actionable insights that drive strategic growth, operational efficiency, and long-term business transformation in highly competitive industries. The company serves a broad spectrum of industry verticals, including Life Sciences, Consumer Goods, Semiconductor and Electronics, Materials and Chemicals, Construction and Manufacturing, Food and Beverages, Energy and Power, Automotive and Transportation, ICT and Media, Aerospace and Defense, and BFSI (Banking, Financial Services, and Insurance). By combining deep domain expertise with advanced analytics, Market Lens IQ delivers comprehensive market assessments, technology trend analysis, investment intelligence, supply chain insights, pricing analysis, customer behavior studies, and future market forecasts tailored to evolving business requirements.
At the core of Market Lens IQ’s capabilities lies a robust 360-degree research methodology integrating primary research, secondary research, expert interviews, data triangulation, AI- powered analytics, and real-time market monitoring. Our research framework ensures the highest standards of data accuracy, reliability, and strategic relevance by leveraging industry databases, corporate filings, government publications, trade journals, regulatory frameworks, white papers, investor presentations, and global economic indicators. The company specializes in identifying emerging market opportunities, disruptive technologies, innovation ecosystems, competitive benchmarking, regulatory shifts, and high-growth investment segments across global industries. Driven by a client-centric approach, Market Lens IQ collaborates with startups, SMEs, multinational enterprises, private equity firms, institutional investors, and Fortune 500 companies to deliver high-value business intelligence solutions that support informed decision-making and sustainable competitive advantage. Through continuous innovation, digital intelligence capabilities, and industry-focused expertise, Market Lens IQ has established itself as a trusted strategic partner in the global market research and consulting landscape, helping organizations navigate market complexities and capitalize on transformative growth opportunities.
In-depth Analysis Tailored to Specified Regions or Segments
Company Profiles Customized to User Preferences
Comprehensive Insights Focused on Specific Segments or Regions
Aortic Aneurysm Repair Market | Global Analysis 2026-2035
Aortic Aneurysm Repair Market
Aortic Aneurysm Repair Market | Global Analysis 2026-2035
Aortic Aneurysm Repair Market by Type (Thoracic Aortic Aneurysm, Abdominal Aortic Aneurysm), by Treatment (Open Surgical Repair, Endovascular Aneurysm Repair, Hybrid Procedures), by Product (Aortic Stent Grafts, Aortic Surgical Grafts, Aortic Repair Accessory Devices), by End Use (Hospitals, Ambulatory Surgery Centers, Other), by Material (Polyester, Polytetrafluoroethylene (PTFE), Polyethylene Terephthalate (PET), Other Materials), by North America (USA, Canada, Mexico), by Europe (Germany, UK, France, Italy, Spain, Rest of Europe), by Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia Pacific), by Latin America (Brazil, Argentina, Rest of Latin America), by Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of MEA) Forecast 2026-2034
Updated On : Nov 4, 2026|Base Year : 2025|Pages : 226
The global aortic aneurysm repair market represents one of the most technologically dynamic segments within cardiovascular devices, driven by an aging population, rising prevalence of degenerative vascular disease, and a structural shift toward minimally invasive interventions. Our proprietary primary research estimates the market at $5.6 billion in 2026, projected to reach $12.9 billion by 2033, expanding at a CAGR of 12.6% . This growth is underpinned by accelerating adoption of endovascular aneurysm repair (EVAR) and thoracic endovascular aneurysm repair (TEVAR), expanding screening programs, and continuous innovation in stent graft technology.
Aortic Aneurysm Repair Market Size (In Billion)
15.0B
10.0B
5.0B
0
4.973 B
2025
5.600 B
2026
6.306 B
2027
7.100 B
2028
7.995 B
2029
9.002 B
2030
10.14 B
2031
Aortic Aneurysm Repair Market Size (In Billion)
Year
Market Size
2025
4.973 B
2026
5.600 B
2027
6.306 B
2028
7.100 B
2029
7.995 B
2030
9.002 B
2031
10.14 B
Abdominal aortic aneurysms (AAA) constitute the largest clinical segment, accounting for 63.3% of total repair procedure value in 2025. Thoracic aortic aneurysms (TAA), while less prevalent, are growing at a faster rate due to improved diagnostic imaging and expanding TEVAR indications. The global burden is substantial: cardiovascular diseases cause approximately 17.9 million deaths annually, representing 32% of all global deaths, per World Health Organization data. In the U.S. alone, AAA prevalence ranges from 0.5% to 3.2% , with ruptures causing approximately 15,000 deaths annually.
North America remains the dominant regional market, capturing 46.0% of global revenue in 2025, followed by Europe at 25% . Asia-Pacific is the fastest-growing region, with India and China registering CAGRs of 15.4% and 14.6% respectively, driven by healthcare infrastructure development and rising awareness.
Key Market Drivers & Restraints
Growth Drivers
Aging Population Demographics: The WHO projects that the global population aged 60 and older will double by 2050, significantly expanding the at-risk pool for aortic aneurysms.
Shift to Minimally Invasive Procedures: EVAR and TEVAR reduce hospital stay, recovery time, and procedural mortality compared to open surgery, accelerating adoption across healthcare systems.
Expanding Screening Programs: National initiatives such as Czechia's pilot AAA screening program for men aged 65-67 (launched February 2025) and Ontario's first AAA screening program for individuals 65 and older (September 2025) are driving earlier diagnosis and treatment.
Technological Advancements: Next-generation stent grafts with improved conformability, fenestrated and branched designs, and AI-powered imaging platforms are expanding treatable patient populations.
Rising Healthcare Expenditure: Increased healthcare spending globally, particularly in emerging markets, is improving access to advanced vascular repair technologies.
Market Restraints
High Device Costs: Advanced stent grafts remain expensive, limiting access in price-sensitive and underfunded healthcare systems.
Anatomical Complexity: Patient-specific device sizing and the need for experienced interventional teams constrain broader adoption in lower-volume centers.
Long-Term Durability Concerns: Endovascular grafts require ongoing surveillance and potential reintervention, adding to lifetime treatment costs.
Regulatory and Reimbursement Hurdles: Varying approval pathways and reimbursement policies across regions slow market penetration.
Segmentation Analysis
By Type
Segment
Market Share (2025)
Growth Outlook
Abdominal Aortic Aneurysm (AAA)
63.3%
Steady growth, driven by EVAR adoption
Thoracic Aortic Aneurysm (TAA)
~36.7%
Faster growth, driven by TEVAR expansion
By Treatment
Treatment Type
Market Share (2025)
Endovascular Aneurysm Repair (EVAR/TEVAR)
54.7%
Open Surgical Repair
~40%
Hybrid Procedures
~5%
By Product
Aortic Stent Grafts: Dominant product category, holding 80.1% of the aortic aneurysm market in 2025. Within the thoracic segment, aortic stent grafts account for 57.6% of product share in 2026.
Aortic Surgical Grafts: Growing in percentage terms, particularly in emerging markets where open surgery remains prevalent.
Aortic Repair Accessory Devices: Supporting procedural delivery, positioning, and sealing, with innovations such as aneurysm sac sealing devices enhancing EVAR outcomes.
By End Use
Hospitals: Largest end-use segment, capturing 78.5% of market revenue in 2025, supported by specialized cardiovascular surgery infrastructure.
Ambulatory Surgery Centers (ASCs): Fastest-growing end-use segment, driven by the shift toward outpatient minimally invasive procedures.
By Material
Polyester: Held 55% of the material segment in 2024, favored for durability and biocompatibility in stent grafts.
Polytetrafluoroethylene (PTFE): Increasingly adopted for its thromboresistance and flexibility.
Polyethylene Terephthalate (PET): Used in specific graft applications.
Regional Outlook
North America leads the global aortic aneurysm repair market with 46.0% revenue share in 2025, driven by high awareness, advanced healthcare infrastructure, and favorable reimbursement. The U.S. remains the largest single market, with AAA prevalence of up to 3.2% in certain populations.
Europe represents approximately 25% of global revenue, supported by national screening programs and a strong regulatory framework. The launch of Czechia's AAA screening pilot in 2025 exemplifies the region's proactive approach.
Asia-Pacific is the fastest-growing region, with India and China as key growth engines. India's CAGR of 15.4% and China's 14.6% reflect rapid healthcare infrastructure development, increasing diagnosis rates, and growing adoption of endovascular techniques. However, only about 1,000 of an estimated 300,000-400,000 individuals with aortic disorders in India receive specialized treatment, highlighting significant unmet need.
Latin America and the Middle East & Africa are emerging markets with growing awareness and improving access, though constrained by limited healthcare budgets and infrastructure.
Competitive Landscape & Strategic Developments
The aortic aneurysm repair market is moderately concentrated, with leading players including Medtronic, W.L. Gore & Associates, Cook Medical, Terumo Corporation, Boston Scientific, Abbott Laboratories, B. Braun Melsungen, Johnson & Johnson, and Artivion. These companies are investing heavily in R&D to advance stent graft technology and expand clinical indications.
Recent strategic developments include:
Medtronic invested over $2.7 billion in R&D during FY2024, focusing on next-generation endovascular stent graft technologies.
Abbott Laboratories invested approximately $2.8 billion in R&D in 2024, advancing cardiovascular screening and diagnostic technologies.
Boston Scientific invested approximately $1.5 billion in R&D in 2024, emphasizing patient-focused minimally invasive vascular therapies.
Bentley reported successful implantation of its BeFlared bridging stent for FEVAR in November 2024, reducing procedure time and preserving artery blood flow.
Life Seal Vascular Inc. received an SBIR grant from the National Science Foundation in July 2024 to develop EVAR technology that minimizes endoleaks.
Fortis Escorts Heart Institute launched a dedicated Aorta Centre in September 2024, offering surgical, endovascular, and hybrid interventions.
Ochsner Health launched The Ochsner Aortic Center in March 2023, adopting AI-powered imaging for safer minimally invasive procedures.
Value Chain Analysis
The aortic aneurysm repair value chain spans raw material suppliers, device manufacturers, distributors, healthcare providers, and patients. Key stages include:
Raw Materials: Polyester, PTFE, and PET resins sourced from specialty chemical suppliers. Quality and biocompatibility are critical.
Device Manufacturing: Complex engineering of stent grafts, including laser-cut nitinol stents and fabric grafts, requiring precision manufacturing and rigorous quality control.
Distribution: Direct sales forces and specialized distributors navigate regulatory pathways and hospital procurement.
Healthcare Providers: Hospitals and ASCs perform procedures, with reimbursement policies influencing adoption.
Post-Market Surveillance: Long-term patient monitoring and device registries support iterative product improvements.
Import/Export & Supplier Dynamics
The aortic aneurysm repair market is characterized by cross-border trade in finished medical devices and specialized components. Major manufacturing hubs include the United States, Europe (particularly Germany and Ireland), and Japan. Emerging markets in Asia-Pacific and Latin America rely heavily on imports for advanced stent grafts.
Key supplier dynamics include:
Concentration of Advanced Manufacturing: A limited number of facilities produce nitinol stents and specialized graft materials, creating supply chain vulnerabilities.
Regulatory Barriers: Import approvals and local registration requirements can delay market entry, particularly in China and India.
Pricing Pressures: Healthcare procurement policies and tender systems influence device pricing and supplier margins.
Localization Trends: Manufacturers are increasingly establishing local production or partnerships in high-growth markets to mitigate supply chain risks and meet local content requirements.
Strategic White-Space Analysis
Significant opportunities exist in:
Expanding TEVAR Indications: Developing devices for complex anatomies, including branched and fenestrated grafts, to treat patients currently ineligible for endovascular repair.
Emerging Markets: Addressing the huge unmet need in India and China through affordable device innovation and physician training programs.
Screening and Early Detection: Partnering with healthcare systems to implement cost-effective screening programs, driving earlier intervention.
AI and Digital Health Integration: Leveraging AI-powered imaging and predictive analytics to improve procedural planning and patient outcomes.
Outpatient and ASC Settings: Developing streamlined devices and protocols for minimally invasive procedures in ambulatory settings.
Methodology
Primary Research
70-80% Primary Research: Our analysis is anchored in extensive primary research, including interviews with C-level executives, procurement directors, interventional cardiologists, vascular surgeons, and regulatory affairs managers across the value chain.
Stakeholder Interviews: We conduct in-depth interviews with hospital procurement heads, clinical trial leads, and device manufacturing executives to capture granular market insights.
Industry Associations: We engage with bodies such as the Society for Vascular Surgery (SVS) , European Society for Vascular Surgery (ESVS) , and Japanese Society for Vascular Surgery (JSVS) to validate clinical trends and adoption patterns.
Quantitative Metrics: Bottom-up market sizing is built using procedure volumes, device average selling prices (ASPs), hospital admission rates, and screening program coverage rates .
Secondary Research & Industry Benchmarking
20-30% Secondary Research: We triangulate primary findings with data from Bloomberg, Factiva, Hoovers, and PitchBook , alongside official sources such as the World Health Organization (WHO) , U.S. Food and Drug Administration (FDA) , European Medicines Agency (EMA) , and national health ministries .
Trade and Industry Data: We reference UN Comtrade for import/export volumes and OECD Health Statistics for healthcare expenditure benchmarks.
Clinical and Regulatory Databases: Data from ClinicalTrials.gov and EU Clinical Trials Register inform pipeline and approval timelines.
Association Reports: Guidance from the Society of Interventional Radiology (SIR) and American Heart Association (AHA) provides clinical context and adoption benchmarks.
Demand Modeling & Market Estimation
Top-Down and Bottom-Up Simultaneously: We model demand by aggregating procedure volumes across regions and device categories (bottom-up) while cross-validating against total healthcare spending and disease prevalence (top-down).
Multi-Level Data Triangulation: Estimates are validated through triangulation across primary interviews, secondary databases, and historical trends.
Procedure-Based Forecasting: Market size is calculated as the product of annual procedure volumes, device penetration rates, and average selling prices , adjusted for regional reimbursement policies.
Scenario Analysis: We develop optimistic, base, and pessimistic scenarios based on regulatory changes, technological adoption curves, and economic factors.
Data Accuracy & Quality Check
Guaranteed Accuracy Level: We ensure 85-90% data accuracy through rigorous validation and cross-referencing.
Real-Time Updates: Every report is updated to the date of purchase, incorporating the latest regulatory approvals, clinical trial results, and market developments.
Quality Assurance Protocol: All data points are reviewed by senior analysts and validated against at least two independent sources.
Transparency: We provide full traceability of data sources and methodologies in the report appendix.
Table 16: Europe Aortic Aneurysm Repair Market Revenue Billion Forecast, by Type 2020 & 2034
Frequently Asked Questions
1. What is the current market size of the aortic aneurysm repair market?
The global aortic aneurysm repair market was valued at **$5.6 billion in 2026** and is projected to reach **$12.9 billion by 2033**, growing at a CAGR of **12.6%** .
2. Which region dominates the aortic aneurysm repair market?
North America holds the largest market share, accounting for **46.0%** of global revenue in 2025, driven by advanced healthcare infrastructure and high awareness.
3. What are the key drivers of the aortic aneurysm repair market?
Key drivers include the aging population, increasing prevalence of cardiovascular diseases, a shift toward minimally invasive EVAR/TEVAR procedures, and expanding screening programs globally.
4. Who are the leading companies in the aortic aneurysm repair market?
Leading players include Medtronic, W.L. Gore & Associates, Cook Medical, Terumo Corporation, Boston Scientific, Abbott Laboratories, and B. Braun Melsungen, among others.
5. What is the fastest-growing segment in the aortic aneurysm repair market?
The endovascular aneurysm repair (EVAR) segment is the fastest-growing treatment type, holding **54.7%** market share in 2025, due to its minimally invasive nature and improved patient outcomes.
Research Methodology & Data Sources
Our rigorous research methodology combines multi-layered approaches with comprehensive quality assurance, ensuring precision, accuracy, and reliability in every market analysis.
Primary Research
70-80% Primary Research: Our analysis is anchored in extensive primary research, including interviews with C-level executives, procurement directors, interventional cardiologists, vascular surgeons, and regulatory affairs managers across the value chain.
Stakeholder Interviews: We conduct in-depth interviews with hospital procurement heads, clinical trial leads, and device manufacturing executives to capture granular market insights.
Industry Associations: We engage with bodies such as the Society for Vascular Surgery (SVS), European Society for Vascular Surgery (ESVS), and Japanese Society for Vascular Surgery (JSVS) to validate clinical trends and adoption patterns.
Quantitative Metrics: Bottom-up market sizing is built using procedure volumes, device average selling prices (ASPs), hospital admission rates, and screening program coverage rates.
Key Stakeholders Interviewed
Key Stakeholders Interviewed
Stakeholder Role
Interview Share (%)
Procurement Director
30%
Interventional Cardiologist
25%
Vascular Surgeon
20%
Regulatory Affairs Manager
15%
Hospital Administrator
10%
Industry Ecosystem Breakdown
Industry Ecosystem Breakdown
Company Type
Representation (%)
Stent Graft Manufacturers
35%
Surgical Device Suppliers
20%
Hospitals & Surgical Centers
25%
Distributors & Procurement Agencies
12%
Regulatory & Reimbursement Bodies
8%
Secondary Research & Industry Benchmarking
20-30% Secondary Research: We triangulate primary findings with data from Bloomberg, Factiva, Hoovers, and PitchBook, alongside official sources such as the World Health Organization (WHO), U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and national health ministries.
Trade and Industry Data: We reference UN Comtrade for import/export volumes and OECD Health Statistics for healthcare expenditure benchmarks.
Clinical and Regulatory Databases: Data from ClinicalTrials.gov and EU Clinical Trials Register inform pipeline and approval timelines.
Association Reports: Guidance from the Society of Interventional Radiology (SIR) and American Heart Association (AHA) provides clinical context and adoption benchmarks.
Demand Modeling & Market Estimation
Top-Down and Bottom-Up Simultaneously: We model demand by aggregating procedure volumes across regions and device categories (bottom-up) while cross-validating against total healthcare spending and disease prevalence (top-down).
Multi-Level Data Triangulation: Estimates are validated through triangulation across primary interviews, secondary databases, and historical trends.
Procedure-Based Forecasting: Market size is calculated as the product of annual procedure volumes, device penetration rates, and average selling prices, adjusted for regional reimbursement policies.
Scenario Analysis: We develop optimistic, base, and pessimistic scenarios based on regulatory changes, technological adoption curves, and economic factors.
Data Accuracy & Quality Check
Guaranteed Accuracy Level: We ensure 85-90% data accuracy through rigorous validation and cross-referencing.
Real-Time Updates: Every report is updated to the date of purchase, incorporating the latest regulatory approvals, clinical trial results, and market developments.
Quality Assurance Protocol: All data points are reviewed by senior analysts and validated against at least two independent sources.
Transparency: We provide full traceability of data sources and methodologies in the report appendix.
11.1.9.2. Products
11.1.9.3. Company Financials
11.1.9.4. SWOT Analysis
11.1.10. MicroPort Scientific Corporation
11.1.10.1. Company Overview
11.1.10.2. Products
11.1.10.3. Company Financials
11.1.10.4. SWOT Analysis
11.1.11. Artivion Inc.
11.1.11.1. Company Overview
11.1.11.2. Products
11.1.11.3. Company Financials
11.1.11.4. SWOT Analysis
11.1.12. Endologix Inc.
11.1.12.1. Company Overview
11.1.12.2. Products
11.1.12.3. Company Financials
11.1.12.4. SWOT Analysis
11.1.13. Lombard Medical
11.1.13.1. Company Overview
11.1.13.2. Products
11.1.13.3. Company Financials
11.1.13.4. SWOT Analysis
11.1.14. CryoLife Inc.
11.1.14.1. Company Overview
11.1.14.2. Products
11.1.14.3. Company Financials
11.1.14.4. SWOT Analysis
11.2. Market Entropy
11.2.1. Company's Key Areas Served
11.2.2. Recent Developments
11.3. Company Market Share Analysis, 2026
11.3.1. Top 5 Companies Market Share Analysis
11.3.2. Top 3 Companies Market Share Analysis
11.4. List of Potential Customers
Figure 17: Europe Aortic Aneurysm Repair Market Revenue Share (%), by Treatment 2026 & 2034
Figure 18: Europe Aortic Aneurysm Repair Market Revenue (Billion), by Product 2026 & 2034
Figure 19: Europe Aortic Aneurysm Repair Market Revenue Share (%), by Product 2026 & 2034
Figure 20: Europe Aortic Aneurysm Repair Market Revenue (Billion), by End Use 2026 & 2034
Figure 21: Europe Aortic Aneurysm Repair Market Revenue Share (%), by End Use 2026 & 2034
Figure 22: Europe Aortic Aneurysm Repair Market Revenue (Billion), by Material 2026 & 2034
Figure 23: Europe Aortic Aneurysm Repair Market Revenue Share (%), by Material 2026 & 2034
Figure 24: Europe Aortic Aneurysm Repair Market Revenue (Billion), by Country 2026 & 2034
Figure 25: Europe Aortic Aneurysm Repair Market Revenue Share (%), by Country 2026 & 2034
Figure 26: Asia Pacific Aortic Aneurysm Repair Market Revenue (Billion), by Type 2026 & 2034
Figure 27: Asia Pacific Aortic Aneurysm Repair Market Revenue Share (%), by Type 2026 & 2034
Figure 28: Asia Pacific Aortic Aneurysm Repair Market Revenue (Billion), by Treatment 2026 & 2034
Figure 29: Asia Pacific Aortic Aneurysm Repair Market Revenue Share (%), by Treatment 2026 & 2034
Figure 30: Asia Pacific Aortic Aneurysm Repair Market Revenue (Billion), by Product 2026 & 2034
Figure 31: Asia Pacific Aortic Aneurysm Repair Market Revenue Share (%), by Product 2026 & 2034
Figure 32: Asia Pacific Aortic Aneurysm Repair Market Revenue (Billion), by End Use 2026 & 2034
Figure 33: Asia Pacific Aortic Aneurysm Repair Market Revenue Share (%), by End Use 2026 & 2034
Figure 34: Asia Pacific Aortic Aneurysm Repair Market Revenue (Billion), by Material 2026 & 2034
Figure 35: Asia Pacific Aortic Aneurysm Repair Market Revenue Share (%), by Material 2026 & 2034
Figure 36: Asia Pacific Aortic Aneurysm Repair Market Revenue (Billion), by Country 2026 & 2034
Figure 37: Asia Pacific Aortic Aneurysm Repair Market Revenue Share (%), by Country 2026 & 2034
Figure 38: Latin America Aortic Aneurysm Repair Market Revenue (Billion), by Type 2026 & 2034
Figure 39: Latin America Aortic Aneurysm Repair Market Revenue Share (%), by Type 2026 & 2034
Figure 40: Latin America Aortic Aneurysm Repair Market Revenue (Billion), by Treatment 2026 & 2034
Figure 41: Latin America Aortic Aneurysm Repair Market Revenue Share (%), by Treatment 2026 & 2034
Figure 42: Latin America Aortic Aneurysm Repair Market Revenue (Billion), by Product 2026 & 2034
Figure 43: Latin America Aortic Aneurysm Repair Market Revenue Share (%), by Product 2026 & 2034
Figure 44: Latin America Aortic Aneurysm Repair Market Revenue (Billion), by End Use 2026 & 2034
Figure 45: Latin America Aortic Aneurysm Repair Market Revenue Share (%), by End Use 2026 & 2034
Figure 46: Latin America Aortic Aneurysm Repair Market Revenue (Billion), by Material 2026 & 2034
Figure 47: Latin America Aortic Aneurysm Repair Market Revenue Share (%), by Material 2026 & 2034
Figure 48: Latin America Aortic Aneurysm Repair Market Revenue (Billion), by Country 2026 & 2034
Figure 49: Latin America Aortic Aneurysm Repair Market Revenue Share (%), by Country 2026 & 2034
Figure 50: Middle East & Africa Aortic Aneurysm Repair Market Revenue (Billion), by Type 2026 & 2034
Figure 51: Middle East & Africa Aortic Aneurysm Repair Market Revenue Share (%), by Type 2026 & 2034
Figure 52: Middle East & Africa Aortic Aneurysm Repair Market Revenue (Billion), by Treatment 2026 & 2034
Figure 53: Middle East & Africa Aortic Aneurysm Repair Market Revenue Share (%), by Treatment 2026 & 2034
Figure 54: Middle East & Africa Aortic Aneurysm Repair Market Revenue (Billion), by Product 2026 & 2034
Figure 55: Middle East & Africa Aortic Aneurysm Repair Market Revenue Share (%), by Product 2026 & 2034
Figure 56: Middle East & Africa Aortic Aneurysm Repair Market Revenue (Billion), by End Use 2026 & 2034
Figure 57: Middle East & Africa Aortic Aneurysm Repair Market Revenue Share (%), by End Use 2026 & 2034
Figure 58: Middle East & Africa Aortic Aneurysm Repair Market Revenue (Billion), by Material 2026 & 2034
Figure 59: Middle East & Africa Aortic Aneurysm Repair Market Revenue Share (%), by Material 2026 & 2034
Figure 60: Middle East & Africa Aortic Aneurysm Repair Market Revenue (Billion), by Country 2026 & 2034
Figure 61: Middle East & Africa Aortic Aneurysm Repair Market Revenue Share (%), by Country 2026 & 2034
Table 17: Europe Aortic Aneurysm Repair Market Revenue Billion Forecast, by Treatment 2020 & 2034
Table 18: Europe Aortic Aneurysm Repair Market Revenue Billion Forecast, by Product 2020 & 2034
Table 19: Europe Aortic Aneurysm Repair Market Revenue Billion Forecast, by End Use 2020 & 2034
Table 20: Europe Aortic Aneurysm Repair Market Revenue Billion Forecast, by Material 2020 & 2034
Table 21: Europe Aortic Aneurysm Repair Market Revenue Billion Forecast, by Country 2020 & 2034
Aortic Aneurysm Repair Market.jpg){kind=small}
